Analgesics

Analgesics is set to maintain steady current value growth in Brazil in 2023, and will remain the largest category within OTC, with a 40% share of value sales. The consumption of analgesics is mainly related to general pain, fever, and the relief of…

In late 2022 and into early 2023, a convergence of COVID-19, seasonal flu, and heightened influenza cases created what the media termed a "tripledemic," impacting Mexico, the US, and Central American nations. While Mexico did not experience the same…

Though current value sales are expected to rise, constant value sales are expected to fall, as continuing rising operating costs cut into profitability. In 2023, with concerns about COVID-19 abating, demand for analgesics reduces to more normal…

Analgesics benefitted from the era of COVID-19, as consumers sought out pain relief such as acetaminophen and ibuprofen, both of which saw extensive coverage in the media as low-cost products that could treat symptoms of the virus quickly and…

Analgesics is set to see a decline in sales in 2023 as consumers have migrated away from aspirin in an uncertain economic environment and sought to prioritise household essentials, while turning to other categories to treat basic ailments such as…